Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) in Brussels and advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law perspective.
From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie e.V. (BPI). Before, he worked as a lawyer at Sträter Law Firm in Germany with a special focus on managed entry agreements and licensing of pharmaceuticals. Dr. Natz has also worked in the field of competition law with the European Commission and in the pharmaceutical industry.
-Are we stuck in the past? Perspectives from the HTA coordination group: the historical structure of healthcare systems and how this needs to change going forward
-The role of the EUHTA and the need to consider ability and willingness to pay from individual countries
-How will the parallel joint collaboration work between member states?
-How prepared is industry?
Invited:
Constanze Blume, Global Regulatory Affairs, BioNTech
Falk Ehmann, Head of Innovation and Development Accelerator, EMA
This panel will explore the practical implications that industry and patient organizations need to consider when engaging given the evolving landscape of HTA in Europe